

## UPDATE TO ENOXAPARIN BIOSIMILAR PRODUCT LISTINGS

Effective August 1, 2021, three enoxaparin biosimilar products (Inclunox<sup>®</sup>, Noromby<sup>®</sup>, and Redesca<sup>®</sup>) were added as Exception Drug Status (EDS) benefits. The reference product is Lovenox<sup>®</sup> (enoxaparin).

Individuals must meet medical criteria to be eligible for EDS. Please refer to the August 1, 2021, Formulary Bulletin #204 for additional information. You can find the bulletin at this link:

<https://formulary.drugplan.ehealthsask.ca/BulletinsInfo>

**Additionally, in order to address some of the unique implementation considerations specific to enoxaparin and the Saskatchewan Health Authority, the following has been extended on a temporary basis:**

**Patients who are initiated on enoxaparin in a hospital and discharged on Lovenox will be considered to have previously been on Lovenox, and will therefore be permitted to continue Lovenox.**

**This has been extended until January 31, 2022. EDS requests for Lovenox for patients started in hospital will be approved by the Drug Plan until that time.**

**Biosimilar versions of enoxaparin will continue to be the preferred enoxaparin options and coverage will be available for patients if the physician chooses to prescribe one of the biosimilar options.**

## REMINDERS

Lovenox<sup>®</sup>, Inclunox<sup>®</sup>, Noromby<sup>®</sup>, and Redesca<sup>®</sup> are NOT interchangeable. All EDS requests for enoxaparin must indicate the specific brand prescribed.

Patients with a current Lovenox<sup>®</sup> EDS approval will continue to be approved for Lovenox<sup>®</sup> if criteria is met.

**For patients who do not have a current Lovenox<sup>®</sup> EDS approval (NEW clients), only Inclunox<sup>®</sup>, Noromby<sup>®</sup>, or Redesca<sup>®</sup> biosimilars will be considered for EDS.**

Pharmacies should contact the prescriber to request a prescription for one of the biosimilar products (Inclunox<sup>®</sup>, Noromby<sup>®</sup>, or Redesca<sup>®</sup>) if the prescription does not clearly indicate a specific brand.

Pharmacies should also ensure they are able to obtain the biosimilar product from the wholesaler.

***Reminder:***

**Lovenox® and biosimilar enoxaparin products are not interchangeable.**

**Who to Call:**

**If you or your patients have any questions, please call:**

- Drug Plan and Extended Benefits Branch at 306-787-8744 (Regina) or 1-800-667-2549

**Information is also available on the following websites:**

- The secure Drug Plan web page for pharmacies (site where paylists and bulletins are listed):  
<https://www.drugplan.health.gov.sk.ca>